 Precision BioSciences Inc NASDAQ: DTIL and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precisions PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precisions PCSK9-directed ARCUS nuclease to develop additional gene-editing therapies for genetic diseases, initially targeting liver diseases. 